Flow Cytometry
流式细胞术
基本信息
- 批准号:7695941
- 负责人:
- 金额:$ 35.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-08-28 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:5-(6)-carboxyfluorescein diacetate succinimidyl esterAntigensApoptosisArtsBIRC4 geneBiological AssayBromodeoxyuridineCancer CenterCancer Center Support GrantCancer Immunology ScienceCaspaseCell divisionCellsClinical ResearchCommunitiesConfocal MicroscopyCore FacilityCyclinsDNADetectionDevelopmentEmployeeEnvironmentEventFacultyFlow CytometryFluorescence-Activated Cell SortingFundingFutureGalactosidaseGoalsGrantGreen Fluorescent ProteinsGrowth FactorHourImage AnalysisImmunologyLaboratoriesLaser MicroscopyLaser Scanning CytometryLasersLifeMalignant - descriptorMembrane PotentialsMethodsMicroscopyMissionMitochondriaMolecularMolecular CytogeneticsMolecular and Cellular BiologyMultiparametric AnalysisNCI Center for Cancer ResearchNGFR ProteinNerve Growth Factor ReceptorsNormal CellNumbersOperative Surgical ProceduresPCNA genePaperPeer ReviewPeer Review GrantsPhenotypePrincipal InvestigatorProteinsPublishingRecording of previous eventsRegulationReproduction sporesResearchResearch ActivityResearch PersonnelResidual NeoplasmScientistServicesSignal TransductionSiteSorting - Cell MovementStem cell transplantStem cellsSystemTP53 geneTechniquesTechnologyTimeTravelcancer cellcancer immunology functioncancer preventioncell analyzercellular imagingdigitalfluorescence activated cell sorter deviceinstrumentleukemiamalignant breast neoplasmmelanomamemberpeerprogenitorprogramssingle cell analysistransgene expressiontumorigenesis
项目摘要
The Flow Cytometry and Cellular Imaging Core Facility (FCCICF) provides cellular analysis to investigators
with peer-reviewed grants. The FCCICF has two sites, on the north campus and on the recently-opened
south campus. It occupies 1900 sq. ft. and is directed by Dr. Michael Andreeff. The FCCICF develops and
provides techniques for single-cell analysis. Cell phenotyping, proliferation, signaling and apoptosis assays
have been established and modified for multiparametric analysis. Immunophenotypic analysis was combined
with assays of intracellular proteins related to apoptosis (Bcl-2, Bcl-XL, BAG-1, p53, Rb, caspase activation,
mitochondria! membrane potential and Fas), cell signaling (MARK), proliferation (Ki67, cyclins, BrDU, PCNA,
DNA) and cell division history (CFSE). Quantitation of cellular antigens allows determination of the antibodybinding
capacity per cell. Rare events and progenitor/stem cell subpopulations can be detected and isolated
by three-laser excitation/eight-parameter fluorescence-activated cell sorting (FACS) for subsequent analysis
by molecular cytogenetic and other molecular techniques including quantitation of intracellular PKCoc, Bax,
Bcl-2, ERK, pERK, XIAP by laser scanning cytometry. FISH has been combined with apoptosis assays to
discriminate apoptosis in normal and malignant cells. The number, phenotype and proliferation of minimal
residual disease cells can be determined at levels of one malignant in 30,000 normal cells. Methods for
detection of transgene expression in cells are in place using p-galactosidase (p-gal), nerve growth factor
receptor (NGF-R), and green fluorescent protein (EGFP). Acquisition of 3 new FACS Aria cell sorters and a
four-laser flow cytometer (B&D LSRII) has upgraded the facility to provide state-of-the-art isolation and
analysis. Laser confocal microscopy has been used extensively and was upgraded by acquisition of an
Olympus FV-500 multi-user instrument and a DSU spinning disc confocal system. High-impact studies in
cancer prevention, growth factor signaling in breast cancer, apoptosis regulation in leukemias and multistep
tumorigenesis all utilized confocal microscopy. The FCCICF now utilizes 17 major instrument systems. The
Core supports numerous R01, P01, R21, and SPORE grants. Since the previous review, the number of
users has increased 145% (169 investigators with peer-reviewed grants from 19 different programs). 67% of
users have peer-reviewed funding. During the previous funding period, 11,668 hours of service was
provided. Use has tripled to greater than 7,000 hours estimated for 2007. Future plans are focused on the
continued development and application of cutting-edge technologies in cell analysis.
流式细胞术和细胞成像核心设施(FCCICF)为研究者提供细胞分析
同行评审的赠款FCCICF有两个网站,在北校区和最近开放的
南校区。占地1900平方米。英尺由Michael Andreeff博士指导。FCCICF开发和
提供单细胞分析技术。细胞表型、增殖、信号传导和凋亡测定
已建立和修改的多参数分析。结合免疫表型分析
用与凋亡相关的细胞内蛋白(Bcl-2,Bcl-XL,BAG-1,p53,Rb,半胱天冬酶激活,
线粒体!膜电位和Fas),细胞信号传导(MARK),增殖(Ki 67,细胞周期蛋白,BrDU,PCNA,
DNA)和细胞分裂史(CFSE)。细胞抗原的定量允许确定抗体结合
每个电池的容量。可以检测和分离罕见事件和祖细胞/干细胞亚群
通过三激光激发/八参数荧光激活细胞分选(FACS)进行后续分析
通过分子细胞遗传学和其他分子技术,包括定量细胞内PKCoc,Bax,
激光扫描细胞仪检测Bcl-2、ERK、pERK、XIAP。FISH已与细胞凋亡测定相结合,
区分正常和恶性细胞的凋亡。微小型的数量、表型和增殖
残留的疾病细胞可以被确定为30,000个正常细胞中有一个恶性细胞的水平。方法
使用β-半乳糖苷酶(p-gal)、神经生长因子
受体(NGF-R)和绿色荧光蛋白(EGFP)。购置3台新的FACS Aria细胞分选仪和1台
四激光流式细胞仪(B&D LSRII)已经升级了设备,以提供最先进的分离和
分析.激光共聚焦显微镜已被广泛使用,并通过收购一个
Olympus FV-500多用户仪器和DSU旋转盘共焦系统。高影响力研究
癌症预防,乳腺癌中的生长因子信号传导,白血病中的凋亡调节和多步骤
肿瘤发生都使用共聚焦显微镜。FCCICF现在使用17个主要仪器系统。的
Core支持众多R 01、P01、R21和SPORE赠款。自上次审查以来,
用户增加了145%(169名研究人员,来自19个不同的项目,获得了同行评审的赠款)。67%的
用户有同行评审的资金。在上一个供资期间,
提供了估计2007年的使用量增加了两倍,超过7 000小时。未来计划的重点是
继续开发和应用细胞分析的尖端技术。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL ANDREEFF其他文献
MICHAEL ANDREEFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL ANDREEFF', 18)}}的其他基金
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
- 批准号:
10356325 - 财政年份:2022
- 资助金额:
$ 35.96万 - 项目类别:
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
- 批准号:
10550265 - 财政年份:2022
- 资助金额:
$ 35.96万 - 项目类别:
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
咪啶酮 ONC201 治疗 AML IND125,203 的 Ph1/2 研究 (12/23/2014)
- 批准号:
10663157 - 财政年份:2019
- 资助金额:
$ 35.96万 - 项目类别:
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
咪啶酮 ONC201 治疗 AML IND125,203 的 Ph1/2 研究 (12/23/2014)
- 批准号:
9806956 - 财政年份:2019
- 资助金额:
$ 35.96万 - 项目类别:
P53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia
P53 激活作为急性髓性白血病的新治疗策略
- 批准号:
8499746 - 财政年份:2013
- 资助金额:
$ 35.96万 - 项目类别:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
联合抑制急性髓系白血病中的 CXCR4 和 FLT3-ITD 信号传导
- 批准号:
7897533 - 财政年份:2010
- 资助金额:
$ 35.96万 - 项目类别:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
联合抑制急性髓系白血病中的 CXCR4 和 FLT3-ITD 信号传导
- 批准号:
8056055 - 财政年份:2010
- 资助金额:
$ 35.96万 - 项目类别:
Targeting Microenvironment / Leukemia Cell Interactions in CML
CML 中的靶向微环境/白血病细胞相互作用
- 批准号:
8000073 - 财政年份:2010
- 资助金额:
$ 35.96万 - 项目类别:
Non-genotoxic p53 activation as novel therapeutic concept for lymphoma
非基因毒性 p53 激活作为淋巴瘤的新治疗概念
- 批准号:
7715218 - 财政年份:2009
- 资助金额:
$ 35.96万 - 项目类别:
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
Plerixafor/G-CSF 联合索拉非尼治疗带有 FLT3-ITD Muta 的急性髓性白血病
- 批准号:
7936811 - 财政年份:2009
- 资助金额:
$ 35.96万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:














{{item.name}}会员




